ACM
XENE icon

Altium Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Altium Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,400
Closed -$315K – 17
2025
Q1 		$315K Hold
9,400
– – 0.76% 18
2024
Q4 		$368K Hold
9,400
– – 0.1% 61
2024
Q3 		$370K Buy
+9,400
New +$379K 0.11% 58

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Altium Capital Management's XENE Position: Q2 2025 in Review

Altium Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 60,251 shares — an estimated $2.02M sold.

Altium Capital Management first reported a position in XENE in Q2 2021 and held it in 10 quarters. The position peaked at $15M in Q1 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Altium Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 60,251 Xenon Pharmaceuticals shares in Q2 2025, an estimated $2.02M.
  • Altium Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Altium Capital Management's Xenon Pharmaceuticals position peaked at $15M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.